Detection and Characterization of Focal Liver Lesions: A Japanese Phase III, Multicenter Comparison between Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging and Contrast-Enhanced Computed Tomography Predominantly in Patients with Hepatocellular Carcinoma and Chronic Liver Disease

Investigative Radiology

Volumn 45, Issue 3, 2010, Pages 133-141

  Ichikawa, Tomoaki ^a   Saito, Kazuhiro ^b   Yoshioka, Naoki ^c   Tanimoto, Akihiro ^d   Gokan, Takehiko ^e   Takehara, Yasuo ^f   Kamura, Takeshi ^g   Gabata, Toshifumi ^h   Murakami, Takamichi ⁱ   Ito, Katsuyoshi ^j   Hirohashi, Shinji ^k   Nishie, Akihiro ^l   Saito, Yoko ^m   Onaya, Hiroaki ⁿ   Kuwatsuru, Ryohei ^o   Morimoto, Atsuko ^p   Ueda, Koji ^q   Kurauchi, Masayo ^r   Breuer, Josy ^s  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NIIGATA UNIVERSITY   (Japan)

^h KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

ⁱ OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^l KYUSHU UNIVERSITY   (Japan)

^m HIROSAKI UNIVERSITY   (Japan)

ⁿ IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^o JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^q Higashi Osaka Yamaji Hospital   (Japan)

^r BAYER YAKUHIN LTD   (Japan)

^s BAYER PHARMA AG   (Germany)

more..

Author keywords

CT; Gadoxetic acid; Hepatocellular carcinoma; Liver; MRI; Neoplasms

Indexed keywords

GADOXETIC ACID; SUPERPARAMAGNETIC IRON OXIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INJECTION SITE PAIN; INTERMETHOD COMPARISON; LIVER ARTERIOGRAPHY; LIVER CELL CARCINOMA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PEROPERATIVE ECHOGRAPHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SMELLING DISORDER; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STANDARD; STATISTICAL SIGNIFICANCE;

EID: 77249111813     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181caea5b     Document Type: Article

References (42)

1. Kamel IR, Choti MA, Horton KM, et al. Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization. Radiology. 2003;227:752-757.
2. Reimer P, Jahnke N, Fiebich M, et al. Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology. 2000;217:152-158.
3. Hammerstingl R, Adam G, Ayuso JR, et al. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial. Invest Radiol. 2009;44:168-176.
4. Federle M, Chezmar J, Rubin DL, et al. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the US multicenter phase III clinical trials: efficacy of early imaging. JMagn Reson Imaging. 2000;12:689-701. (Pubitemid 30808465)
5. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase III clinical study. Radiology. 2000;215:727-736.
6. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003;13:1266-1276.
7. Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology. 1995;196:481-488.
8. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4:1-9.
9. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, et al. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology. 1992;183:59-64.
10. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, et al. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med. 1991;22:233-237; discussion 242.
11. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996; 199:177-183.
12. Freeny PC, Marks WM. Computed tomographic arteriography of the liver. Radiology. 1983;148:193-197.
13. Hayashi M, Matsui O, Ueda K, et al. Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. Am J Roentgenol. 1999;172:969-976.
14. Ichikawa T, Ohtomo K, Takahashi S. Hepatocellular carcinoma: detection with double-phase helical CT during arterial portography. Radiology. 1996;198:284-287.
15. Matsui O, Takashima T, Kadoya M, et al. Dynamic computed tomography during arterial portography: the most sensitive examination for small hepatocellular carcinomas. J Comput Assist Tomogr. 1985;9:19-24.
16. Murakami T, Oi H, Hori M, et al. Helical CT during arterial portography and hepatic arteriography for detecting hypervascular hepatocellular carcinoma. Am J Roentgenol. 1997;169:131-135. (Pubitemid 27289622)
17. Couinaud C. Definition of hepatic anatomical regions and their value during hepatectomy [in French]. Chirurgie. 1980;106:103-108.
18. Eliasziw M, Donner A. Application of the McNemar test to non-independent matched pair data. Stat Med. 1991;10:1981-1991.
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
20. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: US multicenter phase III study. Radiology. 2005;237:89-98.
21. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230:266-275.
22. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467.
23. Matsuo M, Kanematsu M, Itoh K, et al. Detection of malignant hepatic tumors: comparison of gadolinium-and ferumoxide-enhanced MR imaging. Am J Roentgenol. 2001;177:637-643.
24. Pauleit D, Textor J, Bachmann R, et al. Hepatocellular carcinoma: detection with gadolinium-and ferumoxides-enhanced MR imaging of the liver. Radiology. 2002;222:73-80.
25. Elizondo G, Weissleder R, Stark DD, et al. Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology. 1990; 174(3 pt 1):797-801. (Pubitemid 20089674)
26. Imai Y, Murakami T, Yoshida S, et al. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology. 2000;32:205-212.
27. Schultz JF, Bell JD, Goldstein RM, et al. Hepatic tumor imaging using iron oxide MRI: comparison with computed tomography, clinical impact, and cost analysis. Ann Surg Oncol. 1999;6:691-698.
28. Stoker J, Romijn MG, de Man RA, et al. Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection of hepatocellular carcinoma. Gut. 2002;51:105-107.
29. Ward J, Naik KS, Guthrie JA, et al. Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. Radiology. 1999;210:459-466.
30. Seneterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology. 1996;200:785-792.
31. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-a multicenter trial. J Comput Assist Tomogr. 2006;30:345-354.
32. Jung G, Breuer J, Poll LW, et al. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Ra-diol. 2006;47:15-23.
33. Kojiro M. Pathology of Hepatocellular Carcinoma. Chichester, United Kingdom: Wiley-Blackwell; 2006.
34. Yoon MA, Kim SH, Park HS, et al. Value of dual contrast liver MRI at 3.0 T in differentiating well-differentiated hepatocellular carcinomas from dys-plastic nodules: preliminary results of multivariate analysis. Invest Radiol. 2009;44:641-649.
35. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPAenhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43:504-511.
36. Kim YK, Kim CS, Chung GH, et al. Comparison of gadobenate dimeglu-mine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocel-lular carcinoma. Am J Roentgenol. 2006;186:149-157.
37. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetic acid (Gd-EOB-DTPA) enhanced MR imaging and multiphasic 64-slice CT for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis. Eur Radiol. 2009;19(suppl 1):S162.
38. Luca A, Grazioli L, Caruso S, et al. A two-centre study for the comparison of Gd-EOB-STPA (Primovist)-enhanced MRI versus triple-phase MDCT for the detection of hepatocellular carcinoma in cirrhosis. Eur Radiol. 2009;19(suppl 1):S162.
39. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol. 2009;44:305-310.
40. Foley WD, Mallisee TA, Hohenwalter MD, et al. Multiphase hepatic CT with a multirow detector CT scanner. Am J Roentgenol. 2000;175:679-685.
41. Murakami T, Kim T, Takamura M, et al. Hypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT. Radiology. 2001;218:763-767.
42. Wong K, Paulson EK, Nelson RC. Breath-hold three-dimensional CT of the liver with multi-detector row helical CT. Radiology. 2001;219:75-79.